Table 2.
Risk of cardiovascular events associated with use of GLP-1 RA use vs. non-use
| N events (IR per 1000 PY) | Non GLP-1 RA (IR per 1000 PY) | GLP-1 RA (IR per 1000 PY) | Adjusted HR (95% CI) | |
|---|---|---|---|---|
| MACE (composite) | 5634 (147.80) | 5569 (148.69) | 65 (97.91) | 0.72 (0.56–0.92) |
| Single components of MACE | ||||
| Stroke | 860 (17.45) | 855 (17.63) | 5 (6.39) | 0.42 (0.18–1.02) |
| Heart failure | 3577 (82.99) | 3535 (83.37) | 42 (60.25) | 0.81 (0.60–1.10) |
| Myocardial re-infarction | 2437 (54.53) | 2409 (54.8) | 28 (38.34) | 0.71 (0.49–1.04) |
| CV death | 1354 (26.56) | 1344 (26.78) | 10 (12.7) | 0.73 (0.39–1.36) |
Model adjusted for: age, sex, smoking, body mass index, eGFR category, comorbidities (heart failure, cancer, hypertension, percutaneous coronary intervention, coronary artery bypass grafting, stroke, peripheral vascular disease, atrial fibrillation, Killip, ST-segment elevation myocardial infarction), and cardiovascular medications (aspirin, statins, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, P2Y12 inhibitors).
CI, confidence interval; CV, cardiovascular; GLP-1 RA, GLP-1 receptor agonist; HR, hazard ratio; IR, Incidence rate; MACE, major adverse cardiovascular event; PY, person-years.